"Solos is putting added emphasis on its MammoView® line of breast endoscopy instrumentation by developing new instruments which will include a new biopsy device to complement its existing line and is in the process of obtaining the necessary regulatory approvals to broaden our markets," stated Bob Segersten, President of Solos Endoscopy, Inc. (SNDY:$0.0058,$0.0008,16.00%)
Solos Endoscopy (SNDY:$0.0058,$0.0008,16.00%) instruments are FDA approved. Upon Solos Endoscopy's receipt of its ISO 13485 Certification, the Company will be able to place the CE Mark on its entire instrument line which will allow it to market the MammoView® Breast Endoscopy Components Internationally.